Program
SHR-1703
A development code. Also written as “SHR-1703 Injection”.
In Jiangsu HengRui Medicine's pipeline, IL-5
. Its studies are mostly in Asthma · Churg-Strauss Syndrome, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Jul 30, 20237 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 73 open or running | phase 3since Jul 30, 2023 | Jul 15, 2020 | Apr 2027phase 1 · NCT07701239 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-1703
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 15, 2020First study: phase 1 study in AsthmaFirst studyNCT04480762 · 42 enrolled · China
- Apr 20, 2021Phase 1 study in AsthmaNCT04855591 · 1 enrolled · Australia
- Jul 20, 2021Phase 1 study in AsthmaNCT05042401 · 23 enrolled · China
- Aug 29, 2022Phase 2 study in Asthma With Eosinophilic PhenotypeNCT05522439 · 85 enrolled · China
- Jul 30, 2023Phase 3 study in Churg-Strauss SyndromeNCT05979051 · 166 planned · China
- May 29, 2024Phase 2 study in Eosinophilic Asthma PatientsNCT06441812 · 200 planned · China
- Jul 9, 2026Phase 1 study in Asthma With Eosinophilic PhenotypeNCT07701239 · 84 planned · China
Ahead
- Apr 2027Primary completion: phase 1 study in Asthma With Eosinophilic PhenotypeNCT07701239
- Sep 2028Primary completion: phase 2 study in Eosinophilic Asthma PatientsNCT06441812
- Dec 2028Primary completion: phase 3 study in Churg-Strauss SyndromeNCT05979051
TargetBeta
“IL-5”the company's pipeline, read by Claude · source
Other programs on IL5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| depemokimabrule | GlaxoSmithKline | phase 4 | 18 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07701239Asthma With Eosinophilic Phenotype · China | 1 | Not yet recruiting | Apr 2027 | 84 |
| NCT06441812Eosinophilic Asthma Patients · China | 2 | Recruiting | Sep 2028 | 200 |
| NCT05979051Churg-Strauss Syndrome · China | 3 | Recruiting | Dec 2028 | 166 |
| NCT05522439Asthma With Eosinophilic Phenotype · China | 2 | Completed | Sep 12, 2024 | 85 |
| NCT05042401Asthma · China | 1 | UNKNOWN | Jun 15, 2023 | 23 |
| NCT04855591Asthma · Australia | 1 | Terminated | Sep 13, 2021 | 1 |
| NCT04480762Asthma · China | 1 | Completed | Sep 21, 2021 | 42 |
How it is read
Names in the registry
- “SHR-1703”, 6 entries
- “SHR-1703 Injection”, 3 entries
Codes read as this program: SHR1703.
Conditions, from the studies’ own filings
- Asthma, 6 studies
- Churg-Strauss Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.